NSIM
CRL icon

North Star Investment Management’s Charles River Laboratories CRL Stock Holding History

North Star Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3
Closed -$588 – 1219
2023
Q3 		$588 Hold
3
– – ﹤0.01% 1190
2023
Q2 		$631 Hold
3
– – ﹤0.01% 1199
2023
Q1 		$605 Hold
3
– – ﹤0.01% 1221
2022
Q4 		$654 Buy
+3
New +$655 ﹤0.01% 1212

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

North Star Investment Management's CRL Position: Q4 2023 in Review

North Star Investment Management sold out of Charles River Laboratories (CRL) in Q4 2023, closing a stake of 3 shares — an estimated $588 sold.

North Star Investment Management first reported a position in CRL in Q4 2022 and held it in 4 quarters. The position peaked at $654 in Q4 2022. 634 funds tracked by Wall St. Rank hold CRL as of Q4 2023.

  • North Star Investment Management reported no remaining Charles River Laboratories position as of Q4 2023 after selling out during the quarter.
  • North Star Investment Management sold 3 Charles River Laboratories shares in Q4 2023, an estimated $588.
  • North Star Investment Management first reported a position in Charles River Laboratories in Q4 2022 and held it in 4 quarters.
  • North Star Investment Management's Charles River Laboratories position peaked at $654 in Q4 2022.
  • 634 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2023.

Based on North Star Investment Management's 13F filing for Q4 2023, filed 10 Jan 2024.